NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, to Its Scientific Advisory Board
NeOnc Technologies (NTHI), a clinical-stage biopharmaceutical company focused on central nervous system (CNS) cancers, has appointed Dr. Alexandra M. Miller to its Scientific Advisory Board. Dr. Miller serves as Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center.
Dr. Miller's expertise in liquid biopsy assays for CNS tumors and cerebrospinal fluid diagnostics will support NeOnc's clinical trials for NEO100™ and NEO212™. The appointment coincides with NeOnc's expansion of its global trial network into the Middle East and India, strengthening the company's position in brain cancer research.
NeOnc Technologies (NTHI), una società biopharmaceutica in fase clinica focalizzata sui tumori del sistema nervoso centrale (SNC), ha nominato la Dott.ssa Alexandra M. Miller al proprio Consiglio Scientifico. La Dott.ssa Miller è Capo dell’Oncologia Neuro e co-direttore del Brain and Spine Tumor Center presso il Perlmutter Cancer Center dell’NYU Langone Health.
L’expertise della Dott.ssa Miller in test di biopsia liquida per tumori CNS e in diagnostica del liquido cerebrospinale supporterà le prove cliniche di NEO100™ e NEO212™. L’ingresso nel consiglio coincide con l’espansione della rete globale di trial di NeOnc verso Medio Oriente e India, rafforzando la posizione dell’azienda nella ricerca sul cancro cerebrale.
NeOnc Technologies (NTHI), una empresa biofarmacéutica en etapas clínicas centrada en los tumores del sistema nervioso central (SNC), ha designado a la Dra. Alexandra M. Miller a su Consejo Científico Asesor. La Dra. Miller es jefa de Neuro-Oncología y co-directora del Brain and Spine Tumor Center en el Perlmutter Cancer Center del NYU Langone Health.
Su experiencia en ensayos de biopsia líquida para tumores del SNC y en diagnósticos del líquido cefalorraquídeo respaldará los ensayos clínicos de NEO100™ y NEO212™. El nombramiento coincide con la expansión de la red global de ensayos de NeOnc hacia Oriente Medio e India, fortaleciendo la posición de la empresa en la investigación del cáncer cerebral.
NeOnc Technologies (NTHI)는 중추 신경계(CNS) 암에 집중하는 임상 단계의 생물의약 회사로, 알렉산드라 M. 밀러 박사를 과학 자문위원회(Scientific Advisory Board)에 임명했습니다. 밀러 박사는 NYU Langone Health의 Perlmutter Cancer Center에서 뇌종양센터의 신경종양학 책임자 겸 뇌-척수 종양 센터 공동 책임자로 재직 중입니다.
밀러 박사의 CNS 종양용 액체 생검 분석 및 뇌척수액 진단 분야의 전문성은 NEO100™ 및 NEO212™의 임상시험을 뒷받침할 것입니다. 이 임명은 중동과 인도로의 글로벌 임상시험 네트워크 확장과 함께 이루어져 뇌암 연구에서 회사의 위치를 강화합니다.
NeOnc Technologies (NTHI), société biopharmaceutique en phase clinique axée sur les cancers du système nerveux central (SNC), a nommé le Dr Alexandra M. Miller à son Conseil scientifique consultatif. Le Dr Miller est chef de Neuro-Oncologie et co-directeur du Brain and Spine Tumor Center au Perlmutter Cancer Center de NYU Langone Health.
Son expertise des tests de biopsie liquide pour les tumeurs du SNC et des diagnostics du liquide cérébrospinal soutiendra les essais cliniques de NEO100™ et NEO212™. Cette nomination coïncide avec l’extension du réseau mondial d’essais de NeOnc vers le Moyen-Orient et l’Inde, renforçant la position de l’entreprise dans la recherche sur le cancer du cerveau.
NeOnc Technologies (NTHI), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf Krebsarten des zentralen Nervensystems (ZNS) konzentriert, hat Dr. Alexandra M. Miller in seinen Wissenschaftlichen Beirat berufen. Dr. Miller ist Leiterin der Neuro-Onkologie und Co-Direktorin des Brain and Spine Tumor Center am Perlmutter Cancer Center der NYU Langone Health.
Die Expertise von Dr. Miller in Liquid-Biopsy-Tests für ZNS-Tumoren und in Diagnostik des Liquor cerebrospinalis wird die klinischen Studien von NEO100™ und NEO212™ unterstützen. Die Ernennung fällt mit der Erweiterung des globalen Studiennetzwerks von NeOnc in den Nahen Osten und Indien zusammen und stärkt die Position des Unternehmens in der Gehirnkrebsforschung.
NeOnc Technologies (NTHI)، شركة أدوية حيوية طَوْرِيّة في مرحلة سريرية تتركّز على سرطانات الجهاز العصبي المركزي، قد عيّنت الدكتورة ألكسندرا م. ميلر في مجلسها الاستشاري العلمي. تعمل الدكتورة ميلر كأُول رئيسة لأورام الأعصاب ومشاركة مديرة مركز Brain and Spine Tumor في Perlmutter Cancer Center بجامعة NYU Langone Health.
سيُدعم خبرة الدكتورة ميلر في اختبارات الخزعة السائلة لأورام الجهاز العصبي المركزي وتشخيص السائل النخاعي الدماغي التجارب السريرية لـ NEO100™ وNEO212™. يواكب تعيينها توسع NeOnc لشبكتها العالمية من التجارب ليشمل الشرق الأوسط والهند، مما يعزز موقع الشركة في أبحاث سرطان الدماغ.
NeOnc Technologies (NTHI)，一家聚焦中枢神经系统（CNS）肿瘤的临床阶段生物制药公司，已任命 阿历山德拉·M·米勒博士 加入其科学咨询委员会。米勒博士现任纽约大学朗格尼医院 Perlmutter Cancer Center 的神经肿瘤科主任兼脑脊柱肿瘤中心共同主任。
米勒博士在用于CNS肿瘤的液体活检检测以及脑脊液诊断方面的专长将支持 NeOnc 的临床试验，涉及 NEO100™ 与 NEO212™。这一任命恰逢 NeOnc 将全球试验网络扩展至中东和印度，进一步巩固公司在脑癌研究领域的地位。
- None.
- None.
CALABASAS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the appointment of Dr. Alexandra M. Miller to its scientific advisory board. Dr. Miller is the Chief of the Neuro-oncology Program and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, where she specializes in treating patients with primary brain tumors.
“We are thrilled to welcome Dr. Alexandra Miller to our Scientific Advisory Board,” said Amir F. Heshmatpour, Executive Chairman and President of NeOnc Technologies. “Dr. Miller is at the forefront of innovation in neuro-oncology, particularly through her groundbreaking development of liquid biopsy assays for CNS tumors. Her expertise in using cerebrospinal fluid to diagnose, monitor, and track the evolution of gliomas will be invaluable. This deep understanding of tumor genomics will provide critical insights as we advance our clinical trials for NEO100™ and NEO212™, enabling us to better understand treatment response and bring personalized therapies to patients.
“Dr. Miller’s appointment comes as we significantly expand our Scientific Advisory Board in tandem with the growth of our global trial network. With new sites opening across the Middle East and India, her leadership in translational diagnostics will play a central role in ensuring that NeOnc continues to set the standard for innovation and excellence in brain cancer research worldwide.”
Alexandra M. Miller, MD, PhD, NYU Langone Health
Alexandra M. Miller is a neurologist and neuro-oncologist who leads NYU Langone’s Perlmutter Cancer Center Neuro-Oncology Program as Chief of the Division of Neuro-Oncology and Co-Director of the Brain & Spine Tumor Center. Her clinical practice and research focus on primary brain tumors, especially malignant gliomas, where she guides multidisciplinary care and program strategy across a major NCI-designated cancer center. Dr. Miller holds clinical faculty appointments in Medicine and Neurology at NYU Grossman School of Medicine, reflecting her cross-disciplinary work at the interface of neurology, oncology, and clinical trials. Her leadership posts at a top academic center underscore her reputation and profile, significant invited talks, program development, and collaborative research networks in neuro-oncology.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8e11179c-b16e-4bf3-b7fd-5b142515b104
FAQ
Who is Dr. Alexandra Miller and what is her role at NeOnc Technologies (NTHI)?
How will Dr. Miller's expertise benefit NeOnc Technologies (NTHI)?
What clinical trials is NeOnc Technologies (NTHI) currently conducting?
Where is NeOnc Technologies (NTHI) expanding its clinical trial network?
